- The key vendors in the global preventive asthma drugs market 2015-2019 are AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, and Novartis.
London, 29 September 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the global preventive asthma drugs market 2015-2019. Biologics are increasingly becoming the preferred choice to treat asthma. They block interleukins, which cause inflammation in the respiratory tract. Xolair by Genentech and Novartis is the only approved biologic drug available in the market for the treatment of asthma. The global preventive asthma drugs market is expected to grow at a CAGR of 5.2% during the forecast period of 2014-2019.
The global preventive asthma drugs market is estimated to witness high growth during the forecast period because of the presence of late-stage pipeline molecules, which are expected to be approved and drive the market despite the loss of patent exclusivity of major drugs. This will lead to the entry of generics into the market. The increased prevalence of asthma, the use of combination drugs in general, and the growing popularity of ICS/LABA combination drugs in particular will drive the growth of the market during the forecast period.
“Pharmaceutical companies are developing drugs that have better safety and efficacy profiles than those already available in the market. These drugs are undergoing clinical trials or are awaiting approval by regulatory agencies,” says Faisal Ghaus, Vice President of Technavio Research.
“NVA237 by Novartis and mepolizumab by GlaxoSmithKline are among the most promising drugs for the treatment of asthma.”
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
If you are interested in more information on this topic and our upcoming research on the Global Preventive Asthma Drugs Market 2015-2019, please send an e-mail to media@TechNavio.com
Follow us on Twitter @Technavio
Like us on Facebook
Follow us LinkedIn
Connect with us on Google+
